Urology Unit, AOUI Verona
Welcome,         Profile    Billing    Logout  
 4 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Antonelli, Alessandro
NCT05830747: Effect of Pre-emptive Dose of Prednisone Versus Placebo in Impacted Third Molar Surgery

Completed
4
34
Europe
Prednisone, Placebo
University Magna Graecia
Facial Swelling, Tooth Position Anomalies, Tooth, Impacted, Tooth Extraction Status Nos, Tooth Avulsion
10/22
12/22
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
UplighTED, NCT06307613: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Recruiting
3
108
Europe, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Thyroid Eye Disease
02/26
10/27
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
OLIGOS, NCT06273345: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate

Recruiting
N/A
150
Europe
Istituto Oncologico Veneto IRCCS
Oligometastatic Prostate Carcinoma
01/26
01/26
COMPAR-K, NCT06290427: Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney

Recruiting
N/A
30
Europe
DaVinci RAPN, Hugo RAS RAPN
Azienda Ospedaliera Universitaria Integrata Verona
Renal Carcinoma
12/24
06/25
COMPAR-P, NCT05766163: Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Prostate

Recruiting
N/A
150
Europe
DaVinci RARP, DaVinci® Surgical System, Hugo RARP, Hugo™ RAS System, Versius RARP, Versius® Robotic Surgery System
Azienda Ospedaliera Universitaria Integrata Verona
Prostate Cancer
03/24
09/24
Hydeal Cyst, NCT06245603: A Study to Evaluate Efficacy and Safety of ® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Recruiting
N/A
200
Europe
Hydeal Cyst®
Istituto Oncologico Veneto IRCCS, Fidia Farmaceutici s.p.a.
Non-muscle Invasive Bladder Cancer
12/26
06/27
ITCO, NCT04031339: Study of Clinical Outcomes of Thyroid Cancer

Recruiting
N/A
15000
Europe
Standard treatment
University of Roma La Sapienza, Italian Thyroid Cancer Observatory (ITCO) Foundation, Catholic University of the Sacred Heart
Thyroid Neoplasms
01/25
01/25
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Active, not recruiting
N/A
280
Europe, Canada, US
GAG score
Elypta
Clear Cell Renal Cell Carcinoma
05/25
12/25
NCT05479422: Optilume Registry for Treatment of Stricture of the Anterior Urethra

Active, not recruiting
N/A
150
Europe
European Association of Urology Research Foundation, Laborie Medical Technologies Inc.
Anterior Urethral Stricture, Male
08/29
08/29
i-RECORd, NCT05363657: International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Recruiting
N/A
10000
Europe, Japan, US, RoW
Partial Nephrectomy (PN), Radical Nephrectomy (RN), Ablation therapy (AT), Active Surveillance (AS)
Azienda Ospedaliero-Universitaria Careggi, Società Italiana di Urologia (SIU), Italian Group for Advanced Laparo-Endoscopic and Robotic Urologic Surgery (AGILE)
Kidney Cancer
12/23
12/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Antonelli, Alessandro
NCT05830747: Effect of Pre-emptive Dose of Prednisone Versus Placebo in Impacted Third Molar Surgery

Completed
4
34
Europe
Prednisone, Placebo
University Magna Graecia
Facial Swelling, Tooth Position Anomalies, Tooth, Impacted, Tooth Extraction Status Nos, Tooth Avulsion
10/22
12/22
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
UplighTED, NCT06307613: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Recruiting
3
108
Europe, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Thyroid Eye Disease
02/26
10/27
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
OLIGOS, NCT06273345: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate

Recruiting
N/A
150
Europe
Istituto Oncologico Veneto IRCCS
Oligometastatic Prostate Carcinoma
01/26
01/26
COMPAR-K, NCT06290427: Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney

Recruiting
N/A
30
Europe
DaVinci RAPN, Hugo RAS RAPN
Azienda Ospedaliera Universitaria Integrata Verona
Renal Carcinoma
12/24
06/25
COMPAR-P, NCT05766163: Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Prostate

Recruiting
N/A
150
Europe
DaVinci RARP, DaVinci® Surgical System, Hugo RARP, Hugo™ RAS System, Versius RARP, Versius® Robotic Surgery System
Azienda Ospedaliera Universitaria Integrata Verona
Prostate Cancer
03/24
09/24
Hydeal Cyst, NCT06245603: A Study to Evaluate Efficacy and Safety of ® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Recruiting
N/A
200
Europe
Hydeal Cyst®
Istituto Oncologico Veneto IRCCS, Fidia Farmaceutici s.p.a.
Non-muscle Invasive Bladder Cancer
12/26
06/27
ITCO, NCT04031339: Study of Clinical Outcomes of Thyroid Cancer

Recruiting
N/A
15000
Europe
Standard treatment
University of Roma La Sapienza, Italian Thyroid Cancer Observatory (ITCO) Foundation, Catholic University of the Sacred Heart
Thyroid Neoplasms
01/25
01/25
AUR87A, NCT04006405: AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Active, not recruiting
N/A
280
Europe, Canada, US
GAG score
Elypta
Clear Cell Renal Cell Carcinoma
05/25
12/25
NCT05479422: Optilume Registry for Treatment of Stricture of the Anterior Urethra

Active, not recruiting
N/A
150
Europe
European Association of Urology Research Foundation, Laborie Medical Technologies Inc.
Anterior Urethral Stricture, Male
08/29
08/29
i-RECORd, NCT05363657: International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Recruiting
N/A
10000
Europe, Japan, US, RoW
Partial Nephrectomy (PN), Radical Nephrectomy (RN), Ablation therapy (AT), Active Surveillance (AS)
Azienda Ospedaliero-Universitaria Careggi, Società Italiana di Urologia (SIU), Italian Group for Advanced Laparo-Endoscopic and Robotic Urologic Surgery (AGILE)
Kidney Cancer
12/23
12/28

Download Options